Arena Pharmaceuticals (NASDAQ: ARNA ) held a press conference in conjunction with its second-quarter earnings to let investors know what's happening with its obesity drug Belviq and the rest of its pipeline.
Since the year began, the SPDR S&P Biotech ETF has soared 22%. By comparison, shareholders in Arena Pharmaceuticals (NASDAQ: ARNA ) have endured a multi-month downtrend, with their stock down 31% year-to-date and underperforming the biotech ...
Arena Pharmaceuticals (NASDAQ: ARNA ) and Orexigen's (NASDAQ: OREX ) novel anti-obesity pills are among three drugs that the FDA has approved for use alongside diet and exercise to promote weight loss.
The biotech sector has performed well this year, with Intercept Pharmaceuticals Inc. (ICPT) and Gilead Sciences, Inc. (GILD) topping the list. Most biopharmaceuticals have so far registered positive gains in 2014, after overcoming the momentum sell-off ...
SAN DIEGO, Sept. 2, 2014 /PRNewswire/ -- Arena Pharmaceuticals, Inc. ARNA, -1.67% today announced that the US Food and Drug Administration (FDA) has granted orphan drug status to APD811 for the treatment of pulmonary arterial hypertension.
Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) showing optimistic movement during previous trade, it traded with the volume of 2.85 million shares in the last trading session, as compared to average volume of 4.66 million shares.
Contrave is a combination of two Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) and Vivus Inc. drugs that were approved by the FDA in 2012, ABC News reports, after having spent 13 years without approving any weight-loss medication.